Repligen Co. (NASDAQ:RGEN) to Post Q3 2024 Earnings of $0.42 Per Share, William Blair Forecasts

Repligen Co. (NASDAQ:RGEN) – Research analysts at William Blair upped their Q3 2024 earnings estimates for Repligen in a note issued to investors on Thursday, May 2nd. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings of $0.42 per share for the quarter, up from their prior estimate of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. William Blair also issued estimates for Repligen’s Q4 2024 earnings at $0.47 EPS, FY2024 earnings at $1.46 EPS and FY2025 earnings at $2.24 EPS.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the prior year, the firm posted $0.64 earnings per share. The company’s revenue was down 17.1% on a year-over-year basis.

A number of other research firms also recently weighed in on RGEN. Stifel Nicolaus boosted their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. JPMorgan Chase & Co. dropped their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, KeyCorp boosted their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $197.75.

Repligen Trading Down 0.2 %

Shares of NASDAQ RGEN opened at $167.72 on Monday. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.37 billion, a PE ratio of 670.91, a P/E/G ratio of 5.58 and a beta of 1.03. The company has a 50-day moving average of $179.84 and a two-hundred day moving average of $174.62. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13.

Insider Buying and Selling at Repligen

In other news, COO James Bylund sold 4,373 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Retirement Systems of Alabama grew its position in Repligen by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock valued at $11,693,000 after purchasing an additional 288 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in Repligen by 1.5% in the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after purchasing an additional 159 shares in the last quarter. International Assets Investment Management LLC grew its position in Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares in the last quarter. American Century Companies Inc. grew its position in Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after purchasing an additional 107,570 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in Repligen in the fourth quarter valued at $2,625,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.